Ascendis Pharma (ASND) Misses Q4 EPS by 775c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR10.40), EUR7.75 worse than the analyst estimate of (EUR2.65). Revenue for the quarter came in at EUR51.17 million versus the consensus estimate of EUR19.55 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Macquarie Assumes ZTO Express (ZTO) at Outperform
• Venture Global exports 127 LNG cargos in Q2 2026